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Dr Bruce M. Elliott (Charleston, SC). I’d like to thank the
authors for providing me a copy of their manuscript prior to the
meeting and the Society for the honor of discussing their work
today. The authors assert that much has been published on lower
extremity bypass grafting and the corresponding impact of diabetes
on both patency and limb salvage rates. Despite recent zealous
enthusiasm for all things endovascular in the superficial femoral
artery, little has been written about the impact of diabetes on
endovascular interventions in the SFA.
The authors report a 20-year experience with 525 limbs in 427
patients undergoing endoluminal treatment of the SFA, entered
into their vascular registry database. One-half of the patients and
one-half of the limbs were in nondiabetic patients, while the
diabetic limbs were equally composed of insulin and non-insulin-
requiring diabetes. There were significantly more advanced comor-
bidities in the insulin-requiring diabetics than in the nondiabetics,
all associated with either reduced limb salvage or survival, notably
end stage renal disease and congestive heart failure.
The indications for intervention were significantly different
between patients with diabetes and those without. Only 25% of the
nondiabetic patients were treated for critical ischemia, while over
half of those with diabetes had critical ischemia and fully one-third
of those had tissue necrosis three times the incidence observed in
the non-diabetic patients. Despite the more advanced degree of
ischemia in those patients with diabetes as opposed to those
without, tibial outflow status and distribution of TASC A/B and
C/D lesions were seemingly unrelated.
Initial technical success was achieved in 93% of patients with-
out any difference between those with and without diabetes.
Although primary patency approximating 60% in 2 years was
equivalent in all groups and assisted patency only slightly worse in
those with insulin-requiring diabetes, limb salvage was substan-
tially worse in diabetic limbs as opposed to those without, 74%
versus 94% at two years.
The authors correctly observed, using Cox proportional haz-
ard analysis, that the more advanced the disease (ie, TASC C/D),
calcification, acute versus chronic occlusion or embolism, technical
complications such as perforation or embolization, all influencedserved, the presence of end-stage renal disease or dialysis indepen-
dently and negatively influenced limb salvage.
The authors conclude that endoluminal therapy for SFA oc-
clusive disease results in lower limb salvage rates for patients with
diabetes as compared to those without, despite similar patency
rates.
I have several questions for the authors. Was there a significant
difference in limb salvage between those with and without diabetes
who had tissue necrosis as their presenting symptom? Was there a
significant difference in limb salvage between those with and
without diabetes when matched for comparable TASC lesions and
tibial continuity? Did the location of the treated lesion, a proximal
SFA versus a distal SFA or popliteal lesion, influence outcome? And
finally, in how many patients were stents utilized, and were you
able to compare their results in similar TASC lesions between
diabetic patients and those without diabetes?
I’d like to thank the Society for the honor of discussing this
paper and congratulate the authors on a worthwhile endeavor.
Dr Andrew M. Bakken. With respect to your first question,
we did separate out the patients based on whether they had
claudication or critical ischemia. The limb salvage rates were sig-
nificantly reduced for diabetic groups in those presenting with
critical ischemia. We did not separate out those presenting with
tissue loss.
One of your follow-up questions was whether TASC lesions
severity impacted this or tibial continuity. The tibial outflow was
equivalent between all of our groups regardless of mode of presen-
tation. If we look specifically at those lesions that were TASC C or
D among the patients presenting with critical ischemia, reduced
limb salvage did persist. Among patients with TASC A or B lesions
presenting with critical ischemia, diabetes did not significantly
impact limb salvage.
With respect to the disease location, we did find a significant
association. Those patients presenting with critical ischemia had
greater below knee popliteal disease involvement and significantly
reduced limb salvage rates.
The final question related to stent usage. Overall stent usage in
these patients was about 37% and whether or not patients receiving
stents were diabetic fared better or worse than those who were not
diabetic was not shown to be significant.
